Related Experiment Video
Updated: Aug 8, 2026
Rotating the Intraocular Lens to Prevent Posterior Capsular Opacification in Cataract Surgeries
Published on: July 7, 2023
Lens cell targetting for gene therapy of prevention of posterior capsule opacification
F Malecaze1, N H Lubsen, B Serre
1INSERM U563, Department of Ophtalmologie et Pathologie des épithéliums, UPS, Faculté de Médecine Toulouse Rangueil, France.
Abstract:
Posterior capsule opacification is the main complication of cataract surgery. Using adenovirus-mediated gene transfer, we recently reported that it was feasible to prevent PCO by overexpressing pro-apoptotic molecules such as pro-caspase 3 or Bax in the residual lens epithelial cells post-cataract surgery. However, this approach is feasible only if gene transfer can be restricted to the residual cells responsible for PCO. Initially, we tested an adenovirus (human serotype 5, HAd5), a lentivirus (HIV) and an oncoretrovirus (MLV) vector for the their in vivo transduction efficiency of rabbit lens cells. We found that HAd5 vectors were the most efficient (>90% of the cells could be transduced). Six potential lens-specific promoters were then cloned into HAd5 vectors and assayed for their ability to target expression to a specific population of cells, using in vitro, ex vivo and in vivo rabbit tissues and human lens capsular bags. We found that the LEP503, MIP and Filensin promoters induced strong lens-specific expression of a reporter gene, in human lens cells. Following this ex vivo assay, we showed in a rabbit PCO model that gene transfer could be spatially restricted to the capsular bag by confining the vector with Matrigel. Our combined approach using a lens-specific promoter and a biocompatible gel should render feasible a novel therapeutic strategy for PCO that targets the remaining lens cells.
Insights
Preventing posterior capsule opacification (PCO) after cataract surgery is possible using gene therapy. A novel approach combines lens-specific promoters with Matrigel to target remaining lens cells, offering a new PCO treatment strategy.
Area of Science:
- Ophthalmology
- Gene Therapy
- Biotechnology
Background:
- Posterior capsule opacification (PCO) is a primary complication following cataract surgery.
- Previous research demonstrated PCO prevention via adenovirus-mediated gene transfer of pro-apoptotic molecules into residual lens epithelial cells.
Purpose of the Study:
- To develop a targeted gene transfer method for preventing PCO.
- To restrict gene delivery specifically to residual lens epithelial cells responsible for PCO.
Main Methods:
- Evaluated transduction efficiency of adenovirus (HAd5), lentivirus (HIV), and oncoretrovirus (MLV) vectors in rabbit lens cells.
- Cloned and tested six lens-specific promoters (LEP503, MIP, Filensin) in HAd5 vectors for targeted expression in human lens cells (in vitro, ex vivo, in vivo).
- Assessed spatial restriction of gene transfer in a rabbit PCO model using Matrigel to confine the vector within the capsular bag.
Main Results:
- HAd5 vectors exhibited the highest transduction efficiency (>90%) in rabbit lens cells.
- LEP503, MIP, and Filensin promoters demonstrated strong, lens-specific reporter gene expression in human lens cells.
- Gene transfer was successfully spatially restricted to the capsular bag in a rabbit PCO model when the vector was combined with Matrigel.
Conclusions:
- A combination of lens-specific promoters and Matrigel enables targeted gene transfer to residual lens cells.
- This approach presents a feasible novel therapeutic strategy for preventing posterior capsule opacification after cataract surgery.
Related Concept Videos
01:25Glaucoma: Overview
01:28Angle Closure Glaucoma: Treatment